ReShape Lifesciences Inc. Quarterly Debt-to-equity in % from Q2 2017 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
ReShape Lifesciences Inc. quarterly Debt-to-equity history and growth rate from Q2 2017 to Q3 2024.
  • ReShape Lifesciences Inc. Debt-to-equity for the quarter ending September 30, 2024 was 96.6 %, a 20.9% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 96.6 -25.5 -20.9% Sep 30, 2024
Q2 2024 91.2 +13.9 +17.9% Jun 30, 2024
Q1 2024 83.5 +29.3 +53.9% Mar 31, 2024
Q4 2023 92.6 +55.8 +152% Dec 31, 2023
Q3 2023 122 +96.2 +371% Sep 30, 2023
Q2 2023 77.4 +57.6 +291% Jun 30, 2023
Q1 2023 54.3 +13 +31.6% Mar 31, 2023
Q4 2022 36.8 -8.85 -19.4% Dec 31, 2022
Q3 2022 25.9 -36.7 -58.6% Sep 30, 2022
Q2 2022 19.8 -75.6 -79.2% Jun 30, 2022
Q1 2022 41.3 -25.8 -38.5% Mar 31, 2022
Q4 2021 45.7 -14.5 -24.1% Dec 31, 2021
Q3 2021 62.7 +31.6 +102% Sep 30, 2021
Q2 2021 95.4 +67.2 +238% Jun 30, 2021
Q1 2021 67.1 +29.2 +76.9% Mar 31, 2021
Q4 2020 60.1 -17.4 -22.5% Dec 31, 2020
Q3 2020 31.1 -90.7 -74.5% Sep 30, 2020
Q2 2020 28.3 -119 -80.7% Jun 30, 2020
Q1 2020 37.9 -98.7 -72.2% Mar 31, 2020
Q4 2019 77.5 -12.7 -14% Dec 31, 2019
Q3 2019 122 +51.6 +73.5% Sep 30, 2019
Q2 2019 147 +91.3 +165% Jun 30, 2019
Q1 2019 137 +94.6 +225% Mar 31, 2019
Q4 2018 90.2 +56.9 +171% Dec 31, 2018
Q3 2018 70.2 +43.1 +159% Sep 30, 2018
Q2 2018 55.5 +0.1 +0.18% Jun 30, 2018
Q1 2018 42 Mar 31, 2018
Q4 2017 33.3 Dec 31, 2017
Q3 2017 27.1 Sep 30, 2017
Q2 2017 55.4 Jun 30, 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.